RedHill Biopharma Limited - Cholangiocarcinoma, Extrahepatic


Not provided

Rare Disease

Cholangiocarcinoma, Extrahepatic


RedHill Biopharma Limited

Access Program Information

This is an expanded access program (EAP) for eligible participants who do not qualify for participation in, or who are otherwise unable to access, the ongoing clinical trial ABC-108. This program is designed to provide access to ABC294640 (Yeliva ®) for treatment of cholangiocarcinoma (CCA) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. An oncologist must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.


Contact: Mark L Levitt, MD, PhD (+972-3-541-3131)


Free Newsletter